212 related articles for article (PubMed ID: 34621816)
1. Combined targeted therapy and immunotherapy for cancer treatment.
Guo CX; Huang X; Xu J; Zhang XZ; Shen YN; Liang TB; Bai XL
World J Clin Cases; 2021 Sep; 9(26):7643-7652. PubMed ID: 34621816
[TBL] [Abstract][Full Text] [Related]
2. Targeted Therapy and Checkpoint Immunotherapy Combinations for the Treatment of Cancer.
Hughes PE; Caenepeel S; Wu LC
Trends Immunol; 2016 Jul; 37(7):462-476. PubMed ID: 27216414
[TBL] [Abstract][Full Text] [Related]
3. Harness the synergy between targeted therapy and immunotherapy: what have we learned and where are we headed?
Liu X; Zhou Q; Xu Y; Chen M; Zhao J; Wang M
Oncotarget; 2017 Oct; 8(49):86969-86984. PubMed ID: 29156850
[TBL] [Abstract][Full Text] [Related]
4. Future perspectives in melanoma research: meeting report from the "Melanoma Bridge": Napoli, December 3rd-6th 2014.
Ascierto PA; Atkins M; Bifulco C; Botti G; Cochran A; Davies M; Demaria S; Dummer R; Ferrone S; Formenti S; Gajewski TF; Garbe C; Khleif S; Kiessling R; Lo R; Lorigan P; Arthur GM; Masucci G; Melero I; Mihm M; Palmieri G; Parmiani G; Puzanov I; Romero P; Schilling B; Seliger B; Stroncek D; Taube J; Tomei S; Zarour HM; Testori A; Wang E; Galon J; Ciliberto G; Mozzillo N; Marincola FM; Thurin M
J Transl Med; 2015 Nov; 13():374. PubMed ID: 26619946
[TBL] [Abstract][Full Text] [Related]
5. Potential role of immunotherapy and targeted therapy in the treatment of cancer: A contemporary nursing practice.
Dailah HG; Hommdi AA; Koriri MD; Algathlan EM; Mohan S
Heliyon; 2024 Jan; 10(2):e24559. PubMed ID: 38298714
[TBL] [Abstract][Full Text] [Related]
6. Epigenetic strategies synergize with PD-L1/PD-1 targeted cancer immunotherapies to enhance antitumor responses.
Chen X; Pan X; Zhang W; Guo H; Cheng S; He Q; Yang B; Ding L
Acta Pharm Sin B; 2020 May; 10(5):723-733. PubMed ID: 32528824
[TBL] [Abstract][Full Text] [Related]
7. Intratumoral immunotherapy: using the tumor as the remedy.
Marabelle A; Tselikas L; de Baere T; Houot R
Ann Oncol; 2017 Dec; 28(suppl_12):xii33-xii43. PubMed ID: 29253115
[TBL] [Abstract][Full Text] [Related]
8. The role of antigen-specific and non-specific immunotherapy in the treatment of cancer.
Monjazeb AM; Hsiao HH; Sckisel GD; Murphy WJ
J Immunotoxicol; 2012; 9(3):248-58. PubMed ID: 22734880
[TBL] [Abstract][Full Text] [Related]
9. Combinatorial Approaches With Checkpoint Inhibitors to Enhance Anti-tumor Immunity.
Seliger B
Front Immunol; 2019; 10():999. PubMed ID: 31178856
[TBL] [Abstract][Full Text] [Related]
10. Overcoming Oncogenic Mediated Tumor Immunity in Prostate Cancer.
Bryant G; Wang L; Mulholland DJ
Int J Mol Sci; 2017 Jul; 18(7):. PubMed ID: 28714919
[TBL] [Abstract][Full Text] [Related]
11. Regulation of cancer-immunity cycle and tumor microenvironment by nanobiomaterials to enhance tumor immunotherapy.
Yang J; Zhang C
Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2020 Jul; 12(4):e1612. PubMed ID: 32114718
[TBL] [Abstract][Full Text] [Related]
12. Do novel treatment strategies enhance T cell-mediated Immunity: Opportunities and challenges in pancreatic cancer immunotherapy.
Luo W; Zheng L; Zhang T
Int Immunopharmacol; 2021 Jan; 90():107199. PubMed ID: 33246828
[TBL] [Abstract][Full Text] [Related]
13. Prospects for combining targeted and conventional cancer therapy with immunotherapy.
Gotwals P; Cameron S; Cipolletta D; Cremasco V; Crystal A; Hewes B; Mueller B; Quaratino S; Sabatos-Peyton C; Petruzzelli L; Engelman JA; Dranoff G
Nat Rev Cancer; 2017 May; 17(5):286-301. PubMed ID: 28338065
[TBL] [Abstract][Full Text] [Related]
14. Emerging Insight into MAPK Inhibitors and Immunotherapy in Colorectal Cancer.
Pancione M; Giordano G; Parcesepe P; Cerulo L; Coppola L; Curatolo AD; Conciatori F; Milella M; Porras A
Curr Med Chem; 2017; 24(14):1383-1402. PubMed ID: 28245767
[TBL] [Abstract][Full Text] [Related]
15. Targeted Therapies in Combination With Immune Therapies for the Treatment of Metastatic Melanoma.
Christiansen SA; Khan S; Gibney GT
Cancer J; 2017; 23(1):59-62. PubMed ID: 28114256
[TBL] [Abstract][Full Text] [Related]
16. Combining targeted therapy with immunotherapy. Can 1+1 equal more than 2?
Robert L; Ribas A; Hu-Lieskovan S
Semin Immunol; 2016 Feb; 28(1):73-80. PubMed ID: 26861544
[TBL] [Abstract][Full Text] [Related]
17. PI3K-AKT-mTOR inhibition in cancer immunotherapy, redux.
O'Donnell JS; Massi D; Teng MWL; Mandala M
Semin Cancer Biol; 2018 Feb; 48():91-103. PubMed ID: 28467889
[TBL] [Abstract][Full Text] [Related]
18. Oncogenic signaling pathways associated with immune evasion and resistance to immune checkpoint inhibitors in cancer.
Kobayashi Y; Lim SO; Yamaguchi H
Semin Cancer Biol; 2020 Oct; 65():51-64. PubMed ID: 31874279
[TBL] [Abstract][Full Text] [Related]
19. Current and Future Applications of Novel Immunotherapies in Urological Oncology: A Critical Review of the Literature.
Özdemir BC; Siefker-Radtke AO; Campbell MT; Subudhi SK
Eur Urol Focus; 2018 Apr; 4(3):442-454. PubMed ID: 29056275
[TBL] [Abstract][Full Text] [Related]
20. Intratumoral Immunotherapy-Update 2019.
Hamid O; Ismail R; Puzanov I
Oncologist; 2020 Mar; 25(3):e423-e438. PubMed ID: 32162802
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
